Aquestive Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
30 TECHNOLOGY DRIVE, WARREN, NJ, 07059
Mailing Address
30 TECHNOLOGY DRIVE, WARREN, NJ, 07059
Phone
908-941-1900
Fiscal Year End
1231
EIN
208623253
Financial Overview
FY2025
$160.43M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 3 Initial insider ownership report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
Annual Reports
10-K
March 4, 2026
- Advanced key pipeline candidates, reaching significant clinical or regulatory milestones.
- Formed or expanded strategic collaborations for development or commercialization.
Insider Trading
STRONG SELL
7 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.